Publications by authors named "John D Sheppard"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

3,956

Total Likes

35

Extended Reach

4,045

Social Features

7
D
Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic Landscape.
John D Sheppard, Kelly K Nichols

Ophthalmol Ther· June 2023

Videos about Article: user user

2 5 4 5

View All Article and Social Media Activity
C
Corneal Staining Responder Analysis: A Clinically Meaningful Dry Eye Outcome.
Esen K Akpek, John D Sheppard, Sonja Krösser

Ophthalmology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease.
Thomas Kaercher, John D Sheppard, Adam Hamm, Esen K Akpek, Sonja Krösser

Graefes Arch Clin Exp Ophthalmol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Neurostimulation, Immunomodulation, Topical Medication Application, and Surgical Reconstruction on Corneal Nerve Function and Regeneration.
Taylor N Drake, John D Sheppard

Eye Contact Lens· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials.
Ahmad M Fahmy, Jennifer S Harthan, David G Evans, Jack V Greiner, Joseph Tauber, John D Sheppard

Front Ophthalmol (Lausanne)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Operating Room Waste Generated From Corneal and Conjunctival Surgeries.
Shambhawi Thakur, John D Sheppard, Medi Eslani, Mark A Pavilack, Brian Philippy

Cornea· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies.
Preeya K Gupta, Rolando Toyos, John D Sheppard, Melissa Toyos, Francis S Mah

Clin Ophthalmol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract.
Esen K Akpek, John D Sheppard, Adam Hamm, Simone Angstmann-Mehr, Sonja Krösser

J Cataract Refract Surg· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.
John D Sheppard, David G Evans, Eugene E Protzko

Am J Manag Care· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing excessive evaporation: an unmet need in dry eye disease.
Paul M Karpecki, Kelly K Nichols, John D Sheppard

Am J Manag Care· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.
John D Sheppard, Fred Kurata, Alice T Epitropoulos, Sonja Krösser, Jason L Vittitow

Am J Ophthalmol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Persistent Epithelial Defect Treatment With Sutureless Cryopreserved and Dehydrated Amniotic Membrane.
Shawn Sell, Martin de la Presa, Shambhawi Thakur, Medi Eslani, Joseph Jeffrey, John D Sheppard

Am J Ophthalmol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Esen K Akpek, David L Wirta, Johnathon E Downing, Joseph Tauber, John D Sheppard

JAMA Ophthalmol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
fungal keratitis: An initial case report and species identification.
Briana Ply, Connie F Cañete-Gibas, Carmita Sanders, Nathan P Wiederhold, Rachel A Dandar, John D Sheppard

Am J Ophthalmol Case Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Dry Eye Disease Severity Impact Efficacy of Varenicline Solution Nasal Spray on Sign and Symptom Treatment Outcomes?
John D Sheppard, Leslie E O'Dell, Paul M Karpecki, Michael B Raizman, Walter O Whitley

Optom Vis Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
Richard L Lindstrom, Amber E Lewis, Edward J Holland, John D Sheppard, John A Hovanesian

J Ocul Pharmacol Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut Microbiome and Its Influence On Ocular Surface and Ocular Surface Diseases.
Shambhawi Thakur, John D Sheppard

Eye Contact Lens· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure.
David Clark, Paul Karpecki, Anne Marie Salapatek, John D Sheppard, Todd C Brady

Clin Ophthalmol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging therapies for dry eye disease.
Lauren Mason, Saad Jafri, Isabelle Dortonne, John D Sheppard

Expert Opin Emerg Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
John D Sheppard, David L Wirta, Eugene McLaurin, Blair E Boehmer, Joseph B Ciolino

Cornea· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study.
Quan Dong Nguyen, Stephen D Anesi, Saradha Chexal, David S Chu, Pouya N Dayani, John D Sheppard

Acta Ophthalmol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes.
Barry A Schechter, John D Sheppard, Christine M Sanfilippo, Heleen H DeCory, Penny A Asbell

Ophthalmol Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Damien F Goldberg, Ranjan P Malhotra, Barry A Schechter, Angela Justice, Sidney L Weiss, John D Sheppard

Ophthalmology· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits.
John D Sheppard, Paul C Cockrum, Angela Justice, Mark C Jasek

Ophthalmol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
Mike Taylor, George Ousler, Gail Torkildsen, Claire Walshe, Matthew C T Fyfe, John D Sheppard

Clin Ophthalmol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis